As of September 30, 89bio had cash, cash equivalents, and short-term investments of $193.3M. This includes $88.2M in net proceeds from the sale of common stock and warrants in a public offering in July.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ETNB:
- 89bio presents additional exploratory analyses from Phase 1b/2a NASH study
- 89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
- 89bio management to meet with Cantor Fitzgerald
- 89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
- 89bio should be bought into rally on Akero data, says RBC Capital
